Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

Patricio G. Schlottmann, MD, discussed investigational imaging systems that may improve detection of peripheral diabetic retinal disease.

By: Patricio G. Schlottmann, MD

Retinal Physician May 18, 2026

5 Key Takeaways

1

Investigational OCTA devices show promise in detecting peripheral diabetic retinal disease.
2

Ultrawidefield OCTA can evaluate patients with diabetic retinopathy and macular edema.
3

These OCTA devices are not yet licensed in the U.S. but are used as investigational tools.
4

OCTA provides a non-invasive method for assessing disease progression without pupil dilation.
5

The technology captures 24-mm images in one go, aiding in the management of diabetic eye disease.

Patricio G. Schlottmann, MD

Affiliations: Charles Centro Oftalmológico

Specialties: Ophthalmology

Bio: Patricio G. Schlottmann, MD, is an ophthalmologist associated with Charles Centro Oftalmológico in Argentina. He received his medical degree from the University of Buenos Aires in 1998 and completed formative clinical training at Santa Lucía Hospital in Buenos Aires, Argentina’s largest public eye hospital. Dr. Schlottmann’s work has centered on ophthalmic care, diagnostic technology, and clinical research. His interest in ocular imaging began during specialist training with exposure to Stratus OCT technology, which led to his first publication in Investigative Ophthalmology and Visual Science and helped shape a career combining clinical practice with research.

PentaVision

Retinal Physician

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

5 Key Takeaways

1

2

3

4

5

Recommendations